These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 22983581

  • 1. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
    Liu CY, Shiau CW, Kuo HY, Huang HP, Chen MH, Tzeng CH, Chen KF.
    Haematologica; 2013 May; 98(5):729-38. PubMed ID: 22983581
    [Abstract] [Full Text] [Related]

  • 2. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF.
    Breast Cancer Res; 2012 Apr 26; 14(2):R68. PubMed ID: 22537901
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC, Chen KC, Chen CC, Cheng AL, Chen KF.
    Oral Oncol; 2012 Jul 26; 48(7):585-93. PubMed ID: 22342571
    [Abstract] [Full Text] [Related]

  • 6. Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
    Yu HC, Hou DR, Liu CY, Lin CS, Shiau CW, Cheng AL, Chen KF.
    PLoS One; 2013 Jul 26; 8(2):e55705. PubMed ID: 23383345
    [Abstract] [Full Text] [Related]

  • 7. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL.
    J Hepatol; 2010 Jan 26; 52(1):88-95. PubMed ID: 19913321
    [Abstract] [Full Text] [Related]

  • 8. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
    Liu CY, Hung MH, Wang DS, Chu PY, Su JC, Teng TH, Huang CT, Chao TT, Wang CY, Shiau CW, Tseng LM, Chen KF.
    Breast Cancer Res; 2014 Sep 17; 16(5):431. PubMed ID: 25228280
    [Abstract] [Full Text] [Related]

  • 9. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
    Yu HC, Hung MH, Chen YL, Chu PY, Wang CY, Chao TT, Liu CY, Shiau CW, Chen KF.
    Cell Death Dis; 2014 Jul 31; 5(7):e1359. PubMed ID: 25077545
    [Abstract] [Full Text] [Related]

  • 10. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.
    Cancer Res; 2008 Aug 15; 68(16):6698-707. PubMed ID: 18701494
    [Abstract] [Full Text] [Related]

  • 11. Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.
    Huang CY, Wei CC, Chen KC, Chen HJ, Cheng AL, Chen KF.
    Cancer Lett; 2012 Apr 01; 317(1):9-15. PubMed ID: 22085493
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL, Chen KF.
    Biochem Pharmacol; 2013 Feb 01; 85(3):356-66. PubMed ID: 23178652
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Differential impact of bortezomib on HL-60 and K562 cells.
    Kliková K, Štefaniková A, Pilchová I, Hatok J, Chudý P, Chudej J, Dobrota D, Račay P.
    Gen Physiol Biophys; 2015 Jan 01; 34(1):33-42. PubMed ID: 25367763
    [Abstract] [Full Text] [Related]

  • 15. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA.
    Mol Cancer Ther; 2006 Sep 01; 5(9):2378-87. PubMed ID: 16985072
    [Abstract] [Full Text] [Related]

  • 16. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D, Kaspers GJ, Assaraf YG, van Meerloo J, Kirk CJ, Anderl J, Blank JL, van de Ven PM, Zweegman S, Jansen G, Cloos J.
    J Hematol Oncol; 2014 Jan 13; 7():7. PubMed ID: 24418325
    [Abstract] [Full Text] [Related]

  • 17. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.
    J Neurosurg; 2013 Dec 13; 119(6):1415-23. PubMed ID: 24093630
    [Abstract] [Full Text] [Related]

  • 18. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
    Zheng B, Zhou R, Gong Y, Yang X, Shan Q.
    Int J Lab Hematol; 2012 Jun 13; 34(3):237-47. PubMed ID: 22145750
    [Abstract] [Full Text] [Related]

  • 19. Role of CIP2A in the antitumor effect of bortezomib in colon cancer.
    Ding Y, Wang Y, Ju S, Wu X, Zhu W, Shi F, Mao L.
    Mol Med Rep; 2014 Jul 13; 10(1):387-92. PubMed ID: 24789441
    [Abstract] [Full Text] [Related]

  • 20. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS.
    Mol Cancer Ther; 2005 Mar 13; 4(3):443-9. PubMed ID: 15767553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.